The ATBCRS brings together the breast cancer research community, spanning basic and clinically-focused research, for two days of updates in cutting-edge translational breast cancer research.
High profile national and international speakers for 2025 include: Otto Metzger (Dana-Farber), Sherene Loi (Peter Mac), Chuck Perou (UNC), Senthil Muthuswamy (NIH), Joakim Lundeberg (KTH), Aziz Al-Khafaji (Broad), Bogda Kocswara (UNSW), Louise Emmett (Garvan), Sean Grimmond (University of Melbourne).
Abstracts for Oral/Poster presentations close 10th September (submit during registration process.
Registration is free but essential
Dr Otto Metzger is a distinguished medical oncologist at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School. His primary research and clinical focus is on breast cancer, particularly invasive lobular carcinoma (ILC) and HER2-positive breast cancer. He has led innovative clinical research with a strong translational component, aimed at improving treatment strategies and predictive biomarkers. He is also an Executive Officer at the Alliance for Clinical Trials in Oncology, contributing to the scientific and operational aspects of clinical trials.
Dr Charles “Chuck” Perou is the May Goldman Shaw Distinguished Professor of Molecular Oncology at the University of North Carolina at Chapel Hill. A leading figure in cancer genomics, he is renowned for groundbreaking work in breast cancer and co-developed the “PAM50” assay, which identified intrinsic molecular subtypes of breast cancer, including the Basal-like subtype prevalent in TNBC. His research integrates genomics, bioinformatics, and clinical data to improve cancer outcomes, with a focus on racial disparities and metastatic disease.
Professor Bogda Koczwara AM is an internationally recognised medical oncologist and a leading clinician-researcher with extensive expertise in cancer survivorship and supportive care. She is the inaugural Director of the Australian Research Centre for Cancer Survivorship, a joint venture of UNSW and Cancer Council NSW. Professor Koczwara established one of Australia's first cancer survivorship programs and drives transformative research in the field through her work in survivorship epidemiology, symptom monitoring, and patient-reported outcomes.
Professor Sherene Loi is a medical oncologist and clinician scientist specialising in breast cancer, she serves as Breast Stream Lead for the Parkville Precinct Cancer Clinical Trials Unit. Professor Loi's groundbreaking work includes demonstrating the prognostic significance of TILs (Tumour-Infiltrating Lymphocytes) in breast cancer, which led to the standardization of TILs as a biomarker in pathology. She has led international clinical trials to advance immunotherapy use for breast cancer. Professor Loi has received numerous accolades, including the Prime Minister's Frank Fenner Prize for Life Scientist of the Year (2021) and induction into the Australian Academy of Health and Medical Sciences. She co-chairs the International Breast Cancer Study Group (IBCSG) and is a Board Director of Breast Cancer Trials Australia and New Zealand.
Joakim Lundeberg is Professor of Molecular Biotechnology at KTH Royal Institute of Technology in Sweden. He leads a research group at the Department of Gene Technology and is affiliated with the Science for Life Laboratory (SciLifeLab), where he previously directed the National Genomics Infrastructure, one of Europe’s top sequencing centers. He is a leading figure in genomics research and is renowned for pioneering Spatial Transcriptomics, a groundbreaking technique that enables spatially resolved RNA sequencing in tissues. He develops innovative methods for nucleic acid analysis and applies them to interdisciplinary life science research, including deep molecular understanding of cancers.
Register or submit an abstract now
